{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:35:23Z","timestamp":1770813323155,"version":"3.50.1"},"reference-count":25,"publisher":"Japan Atherosclerosis Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.5551\/jat.44255","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T18:25:48Z","timestamp":1537467948000},"page":"442-451","source":"Crossref","is-referenced-by-count":5,"title":["Low Baseline High-Sensitive C-Reactive Protein is Associated with Coronary Atherosclerosis Regression: Insights from the MILLION Study"],"prefix":"10.5551","volume":"26","author":[{"given":"Kenji","family":"Sakata","sequence":"first","affiliation":[{"name":"Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadatsugu","family":"Gamou","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenshi","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Ino","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Yamagishi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Masa-aki  Kawashiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"behalf of the MILLION Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Bayturan O, Kapadia S, Nicholls SJ, Tuzcu EM, Shao M, Uno K, Shreevatsa A, Lavoie AJ, Wolski K, Schoenhagen P, Nissen SE, Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol, J Am Coll Cardiol. 2010; 55: 2736-2742","DOI":"10.1016\/j.jacc.2010.01.050"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Ross R, Atherosclerosis-an inflammatory disease, N Engl J Med. 1999; 340: 115-126","DOI":"10.1056\/NEJM199901143400207"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Libby P, Inflammation in atherosclerosis, Arterioscler Thromb Vasc Biol. 2012; 32: 2045-2051","DOI":"10.1161\/ATVBAHA.108.179705"},{"key":"4","unstructured":"4) Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, Butterworth AS, Amouyel P, Assmann G, Bakker SJ, Barr EL, Barrett-Connor E, Benjamin EJ, Bj\u00f6rkelund C, Brenner H, Brunner E, Clarke R, Cooper JA, Cremer P, Cushman M, Dagenais GR, D'Agostino RB Sr, Dankner R, Davey-Smith G, Deeg D, Dekker JM, Engstr\u00f6m G, Folsom AR, Fowkes FG, Gallacher J, Gaziano JM, Giampaoli S, Gillum RF, Hofman A, Howard BV, Ingelsson E, Iso H, J\u00f8rgensen T, Kiechl S, Kitamura A, Kiyohara Y, Koenig W, Kromhout D, Kuller LH, Lawlor DA, Meade TW, Nissinen A, Nordestgaard BG, Onat A, Panagiotakos DB, Psaty BM, Rodriguez B, Rosengren A, Salomaa V, Kauhanen J, Salonen JT, Shaffer JA, Shea S, Ford I, Stehouwer CD, Strandberg TE, Tipping RW, Tosetto A, Wassertheil-Smoller S, Wennberg P, Westendorp RG, Whincup PH, Wilhelmsen L, Woodward M, Lowe GD, Wareham NJ, Khaw KT, Sattar N, Packard CJ, Gudnason V, Ridker PM, Pepys MB, Thompson SG, Danesh J, C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012; 367: 1310-1320"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Ridker PM, Kastelein JJ, Genest J, Koenig W, C-reactive protein and cholesterol are equally strong predictors of cardiovascular risk and both are important for quality clinical care, Eur Heart J. 2013; 34: 1258-1261","DOI":"10.1093\/eurheartj\/eht022"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators, Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease, N Engl J Med. 2005; 352: 29-38","DOI":"10.1056\/NEJMoa042000"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators, C-reactive protein levels and outcomes after statin therapy, N Engl J Med. 2005; 352: 20-28","DOI":"10.1056\/NEJMoa042378"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Razzouk L, Muntner P, Bansilal S, Kini AS, Aneja A, Mozes J, Ivan O, Jakkula M, Sharma S, Farkouh ME, C-reactive protein predicts long-term mortality independently of low-density lipoprotein cholesterol in patients undergoing percutaneous coronary intervention, Am Heart J.2009; 158: 277-283","DOI":"10.1016\/j.ahj.2009.05.026"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Dahl\u00f6f B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators, Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial, Lancet. 2005; 366: 895-906","DOI":"10.1016\/S0140-6736(05)67185-1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ; CAMELOT Investigators, Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial, JAMA. 2004; 292; 2217-2225","DOI":"10.1001\/jama.292.18.2217"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kawashiri MA, Sakata K, Hayashi K, Gamou T, Kanaya H, Miwa K, Ueda K, Higashikata T, Mizuno S, Michishita I, Namura M, Nitta Y, Katsuda S, Okeie K, Hirase H, Tada H, Uchiyama K, Konno T, Ino H, Nagase K, Yamagishi M; Behalf of the MILLION Study Group, Impact of combined lipid lowering and blood pressure control on coronary plaque: myocardial ischemia treated by percutaneous coronary intervention and plaque regression by lipid lowering and blood pressure controlling assessed by intravascular ultrasonography (MILLION) study, Heart Vessels. 2017; 32: 539-548","DOI":"10.1007\/s00380-016-0910-2"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Kawashiri MA, Sakata K, Gamou T, Kanaya H, Miwa K, Ueda K, Higashikata T, Mizuno S, Michishita I, Namura M, Nitta Y, Katsuda S, Okeie K, Hirase H, Tada H, Uchiyama K, Konno T, Hayashi K, Ino H, Nagase K, Terashima M, Yamagishi M, Impact of combined lipid lowering with blood pressure control on coronary plaque regression: rationale and design of MILLION study, Heart Vessels. 2015; 30: 580-586","DOI":"10.1007\/s00380-014-0522-7"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Gamou T, Sakata K, Tada H, Konno T, Hayashi K, Ino H, Yamagishi M, Kawashiri MA; MILLION Study Group, Effect of Reverse Vessel Remodeling on Regression of Coronary Atherosclerosis in Patients Treated With Aggressive Lipid- and Blood Pressure-Lowering Therapy - Insight From MILLION Study, Circ J. 2017; 81: 1490-1495","DOI":"10.1253\/circj.CJ-16-1253"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE, Effect of two intensive statin regimens on progression of coronary disease, N Engl J Med. 2011; 365: 2078-2087","DOI":"10.1056\/NEJMoa1110874"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR, Nissen SE, Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis, JAMA. 2007; 297: 499-508","DOI":"10.1001\/jama.297.5.499"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; ASTEROID Investigators, Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial, JAMA. 2006; 295: 1556-1565","DOI":"10.1001\/jama.295.13.jpc60002"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN; REVERSAL Investigators, Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial, JAMA. 2004; 291: 1071-1080","DOI":"10.1001\/jama.291.9.1071"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE, Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial, JAMA. 2016; 316: 2373-2384","DOI":"10.1001\/jama.2016.16951"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, VidaSimiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group, Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease, N Engl J Med. 2017; 377: 1119-1131","DOI":"10.1056\/NEJMoa1707914"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, Daida H, Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study, Circulation. 2004; 110: 1061-1068","DOI":"10.1161\/01.CIR.0000140261.58966.A4"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Takashima H, Ozaki Y, Yasukawa T, Waseda K, Asai K, Wakita Y, Kuroda Y, Kosaka T, Kuhara Y, Ito T, Impact of lipid-lowering therapy with pitavastatin, a new HMG-CoA reductase inhibitor, on regression of coronary atherosclerotic plaque, Circ J. 2007; 71: 1678-1684","DOI":"10.1253\/circj.71.1678"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, Rifai N, Califf RM, Braunwald E, Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial, Circulation. 2006; 114: 281-288","DOI":"10.1161\/CIRCULATIONAHA.106.628909"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E, C-reactive protein levels and outcomes after statin therapy, N Engl J Med. 2005; 352: 20-28","DOI":"10.1056\/NEJMoa042378"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Amano T, Matsubara T, Uetani T, Kato M, Kato B, Yoshida T, Harada K, Kumagai S, Kunimura A, Shinbo Y, Ishii H, Murohara T, Lipid-rich plaques predict non-target-lesion ischemic events in patients undergoing percutaneous coronary intervention, Circ J. 2011; 75: 157-166","DOI":"10.1253\/circj.CJ-10-0612"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators, Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease, N Engl J Med. 2017; 376: 1713-1722","DOI":"10.1056\/NEJMoa1615664"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/26\/5\/26_44255\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T23:39:07Z","timestamp":1556926747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/26\/5\/26_44255\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.44255","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,1]]}}}